HBV PreS1 Polypeptide and Lentiviral Pseudovirus for Targeted Hepatocyte Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) infection are ineffective, lead to drug resistance, and cannot completely eliminate the virus from the liver, necessitating the development of new antiviral agents and detection systems to address the persistence of HBV and its associated liver diseases.
Innovation Solution
A secreted recombinant polypeptide comprising at least 30 contiguous amino acids of the preS1 region of HBV, fused with an immunoglobulin domain, is used to inhibit HBV infection in hepatocytes, and a lentiviral pseudovirus expressing HBV surface proteins is developed to target and deliver therapeutic agents to liver cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for HBV infection, then viral replication is suppressed, but the virus cannot be completely eliminated and drug resistance develops
Solution Approach 1:
The invention extracts and utilizes the preS1 domain, a specific functional component of the HBV envelope protein, to create recombinant polypeptides that specifically target viral entry mechanisms. By isolating this critical attachment domain and fusing it with immunoglobulin domains, the treatment specifically interferes with viral attachment without requiring complete viral replication suppression, thereby avoiding drug resistance development.
Solution Approach 2:
The recombinant polypeptide acts as an intermediary substance that binds to the preS1 domain and blocks viral attachment to hepatocytes. This intermediary approach prevents direct viral-genome interaction that leads to resistance, instead using a bridging molecule that can be engineered with optimized binding properties and reduced resistance risk.
2Quantity of substance
If conventional antiviral agents are administered, then viral load is reduced, but liver damage persists due to incomplete virus elimination
Solution Approach 1:
The recombinant polypeptide performs preliminary action by blocking viral attachment at the very first step of infection - preventing the virus from binding to hepatocyte surface receptors. By interfering with attachment before entry and replication occur, the treatment prevents subsequent liver damage that results from incomplete virus elimination by conventional agents.
Solution Approach 2:
The invention applies preliminary anti-action by using the preS1-immunoglobulin fusion protein to preemptively block the viral attachment mechanism. This preliminary blocking action occurs before viral entry and replication, preventing the formation of new infectious particles that would cause ongoing liver damage.
3Loss of information
If HBV envelope proteins are studied for vaccine development, then understanding of viral entry is improved, but complexity of protein structure makes effective targeting difficult
Solution Approach 1:
The invention segments the complex HBV envelope protein into its functional domains, specifically isolating the preS1 domain that mediates viral attachment. By focusing on this discrete functional segment rather than the entire complex envelope protein, the invention simplifies the target while maintaining understanding of viral entry mechanisms.
Solution Approach 2:
The invention applies local quality by creating a fusion protein that concentrates the viral binding function in the preS1 domain while the immunoglobulin domain provides standardized, engineered binding and stability properties. This local specialization allows each domain to perform its optimal function without the complexity of the complete native envelope protein.
Data Source
AI summary
A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed.